- Primary and Secondary Efficacy Endpoints Met, Demonstrating Statistically - Significant Reduction in Intra-Ocular Pressure (IOP) for Patients with Glaucoma MELBOURNE, Australia, Feb. 18, 2022 /PRNewswire/ PolyActiva Pty Ltd, a clinical-stage Australian biopharmaceutical company focused on developing unique biodegradable ocular implants with sustained drug delivery for patients suffering from ophthalmic diseases such as glaucoma, today announced that the.
– Primary and Secondary Efficacy Endpoints Met, Demonstrating Statistically – Significant Reduction in Intra-Ocular Pressure (IOP) for Patients with Glaucoma.
A source close to the Carthage Palace in Tunisia has revealed to the Arabi Post that the President, Kais Saied will announce new resolutions on the occasion of the anniversary of the initial spark of .